Determining the extent of liver scarring in patients with psoriasis using a non-invasive scan and assessing the relationship between liver scarring and other potential risk factors for liver damage including methotrexate

Not Applicable

Completed

• Conditions: iver fibrosis in psoriasis; Digestive System; Fibrosis and cirrhosis of liver

• Registration Number: ISRCTN15878562
• Lead Sponsor: ewcastle upon Tyne Hospitals NHS Foundation Trust

Brief Summary

2024 Results article in https://doi.org/10.1093/bjd/ljae069 (added 07/05/2024)

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-17
• Study Completion: 2023-03-30
• Last Update Posted: 3 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

1. Adults > = 18 years of age
2. Ability to consent
3. Chronic plaque psoriasis diagnosed by a dermatologist with a PASI > = 5 at anytime

Exclusion Criteria

1. Pregnancy
2. Potential participants who may have difficulties in adequately understanding written or verbal information in English

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Cumulative dose of methotrexate within 6 months of recruitment, calculated from data collected to identify weekly doses each patient received (mg) over time and adding these up to reach a total dose in gram for every patient<br>2. Liver stiffness measured using Fibroscan within 12 months of recruitment